New drug combo aims to stop blood cancer relapse after transplant

NCT ID NCT07183878

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether adding the targeted drug venetoclax to standard chemotherapy before a stem cell transplant can help prevent cancer from returning in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 60 will be randomly assigned to receive either the enhanced or standard chemo regimen. The main goal is to see if the new combo improves how long patients stay cancer-free after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (a targeted cancer drug) added to standard chemotherapy (busulfan and cyclophosphamide)
What this could lead to: If it works, this could lower the chance of cancer returning after a stem cell transplant for people with high-risk AML or MDS.
What could go wrong: This is a mid-stage trial with 138 participants, so results are not yet proven. Adding venetoclax may increase side effects like infections or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA HIGH RISK ACUTE MYELOID LEUKEMIA HIGH-RISK MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.